PT-141 in women — the HSDD conversation

This experience has a clinical name: it's what the gap between hypoactive sexual desire disorder and medical care looks like in practice.

Hypoactive sexual desire disorder — HSDD — is defined as persistently low or absent desire for sexual activity that causes personal distress. The distress criterion is deliberate and important: it distinguishes HSDD from simply having a lower-than-average libido, which is not a disorder. HSDD is the subset of low desire that the person experiencing it finds distressing — that represents a departure from their own baseline, that affects their sense of self or their relationship in ways they don't want. Estimates suggest it affects roughly 10% of women in the United States, making it among the most common female sexual complaints. The research on recognition and treatment rates suggests most of those women never receive a diagnosis or a pharmacological option.

Part of this is historical. The pharmaceutical category of female sexual dysfunction barely existed before the 2000s. The field of sex research, led primarily by male researchers for most of the twentieth century, was more interested in male sexual dysfunction and treated female desire as either derivative of male desire, primarily psychological in origin, or simply not a medical concern. The DSM-IV didn't have a separate HSDD entry for women; it wasn't until 2013 that the DSM-5 created female sexual interest/arousal disorder as a distinct entity. Clinical medicine has been slow to accept that female sexual desire is a neurobiological phenomenon with addressable pharmacology — the kind of slowness that people experiencing the gap often describe as dismissal.

The pharmacology arrived, eventually, in two waves. The first was flibanserin, approved by the FDA in 2015 under the brand name Addyi — a daily oral medication with a complex mechanism that includes 5-HT1A agonism and 5-HT2A antagonism, with secondary effects on dopamine and norepinephrine. Flibanserin's approval was itself contentious: the FDA initially rejected it twice before approving it under patient advocacy pressure, the trials showed modest effects (about half a satisfying sexual event more per month on average), and the drug carries significant alcohol interaction warnings that limit practical use. It requires daily dosing for effect — more like an antidepressant in its time course than an on-demand treatment. For women who want something they can use when they anticipate sexual activity, flibanserin's pharmacokinetics are the wrong shape.

The second wave was bremelanotide, approved in 2019 as Vyleesi. This one works on a completely different mechanism — centrally activating melanocortin 4 receptors in hypothalamic sexual arousal circuits, driving dopaminergic and oxytocinergic downstream signaling — and it's on-demand rather than daily. The dose is 1.75 mg by subcutaneous self-injection approximately 45 minutes before anticipated sexual activity. Its FDA approval was based on two Phase III trials (the RECONNECT program) in premenopausal women with acquired, generalized HSDD, which showed statistically significant improvements in desire scores and a reduction in distress relative to placebo.

The honest accounting of the effect sizes: modest but real. Women in the bremelanotide group showed roughly 0.5-point improvements in the FSFI desire domain over placebo. Not transformative. Not the difference between not wanting sex and urgently wanting it. More like a measurable shift in the probability that desire arrives when conditions are favorable — a lower threshold rather than a guaranteed experience. For some women in the trials, the effect was more substantial; for others, minimal. The variance in response is wide.

The comparison between flibanserin and bremelanotide has several dimensions. Flibanserin is daily oral — easier to take, no injection required, no planning relative to a specific occasion. Bremelanotide is on-demand — no daily pill, but requires advance planning and a subcutaneous injection. Flibanserin's side effects at steady state include dizziness, somnolence, and the alcohol interaction; bremelanotide's primary side effects are nausea (approximately 40% of users), transient blood pressure elevation, and with repeated use, some risk of hyperpigmentation. Neither drug is without burden. The choice between them depends on patient preference, lifestyle, medical history, and the degree to which daily vs. on-demand dosing aligns with how the person thinks about and experiences their desire pattern.

Neither is a first-line treatment without context. Before either pharmacological option is appropriate, the evaluation should include thyroid function (hypothyroidism is a common reversible cause of desire decline), testosterone levels (testosterone is the primary androgen driving desire in women as in men; below-normal levels are treatable and relevant), psychiatric medication review (SSRIs, SNRIs, and hormonal contraceptives are common desire suppressants), relationship and psychological factors that a prescribing provider may want to refer for concurrent attention, and sleep and stress status, because chronic sleep deprivation and HPA axis dysregulation are themselves reliable desire suppressors.

The premenopausal restriction in Vyleesi's approval deserves acknowledgment. The RECONNECT trials enrolled only premenopausal women — women still cycling, with endogenous estrogen and progesterone — and the drug is approved only for that population. This is a regulatory and scientific boundary, not a pharmacological judgment about postmenopausal women: the trials simply weren't conducted in that population, and the FDA approves drugs based on the populations studied. Postmenopausal women with HSDD — a substantial group, particularly in the years following the genitourinary changes of menopause — have no approved version of this option. Off-label use in postmenopausal women is a clinical decision requiring individual evaluation and is not covered by the approval data.

The relationship between desire disorders and relationship context is something the trials attempted to control for but can never fully eliminate. HSDD in the context of a relationship where desire has declined because of relationship dissatisfaction, conflict, or habituation is a different clinical entity than HSDD driven by neurobiological decline — even though the symptom looks identical from the outside. Bremelanotide acts on the neurobiological component. It cannot address relationship context, communication, emotional safety, or the factors that in many cases are primary. A prescribing provider evaluating HSDD should ideally assess both the biological and relational dimensions, not because one is more real than the other but because the pharmacological tool is useful only for the biological layer.

What the existence of Vyleesi does, beyond the clinical details, is confirm something that women with HSDD have been told in various implicit and explicit ways to doubt: that their experience of desire decline is real, that it has biological underpinning, that it is a recognized medical condition, and that pharmacology can address a meaningful component of it. The modesty of the effect sizes in trials doesn't diminish that. Neither does the imperfect delivery method, the nausea, or the commercial underperformance of the drug. The pharmacological validation of desire as a treatable neurobiological phenomenon — not just a mood or an attitude or a relationship problem that women need to work on — is a statement that took decades to make officially. It's worth noting what it took to get there, and what it means that the door is now open.

Evaluation with a prescribing provider who understands the HSDD diagnosis — who will take the symptom seriously, run appropriate labs, review medications, and have an honest conversation about options and expectations — is where this conversation belongs. The tools now exist. The clinical literacy to use them well is still catching up.